Nuo Therapeutics
OTC: AURXHouston, US · Founded 2001 · Delaware corporation · 20 employees on LinkedIn · 1 known investors
Find your way into Nuo Therapeutics
92 people in our graph share verified history with the Nuo Therapeutics team — schools, employers, funds. One of them is your warm intro.
Costanza Cariniunlockedknows Martin P. Rosendale · together at California State University, Long Beach
×8knows the team · via California State University, Long Beach
×2knows the team · via American Red Cross Biomedical Services
knows the team · via Maryland Tech Council
Nuo Therapeutics is a commercial-stage medical device company developing biodynamic therapies for wound care. Its flagship product, Aurix, is a hematogel that uses a patient's own platelets and plasma to promote healing.
Founders & leadership
PC
Peter ClausenExecutive
MP
Martin P. RosendaleinChief Executive Officer2008–2015Martin P. Rosendale is an engineer and microbiologist with over 30 years of experience in life sciences and medical devices. He has served as CEO five times, founded two companies, and launched, acquired, or commercialized more than 10 products and companies across public, private, and not-for-profit sectors.
AM
Andrew MaslanExecutive
DE
David E. JordenChief Executive and Financial Officer, Secretary, and Director
Board
LA
Lawrence AtinskyBoard director
JD
Joseph Del GuercioBoard director
LH
Lyle HohnkeBoard director
SP
Scott PittmanBoard director
PM
Paul MintzBoard director
CE
C. Eric WinzerinMember Board of Directors & Audit Committee ChairChief Financial Officer and Director at Immunomic Therapeutics
JB
James BensonBoard director
MM
Mark McLoughlinBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$37.2M disclosed across 10 of 11 rounds · 1900–2025
▶$791.4KraisedAug 2025 · 9 investors · Other Health CareRule 506(b)
▶$791.4KraisedAug 2025 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David JordenExecutive Officer, Director
- Paul MintzDirector
- Peter ClausenExecutive Officer
- C Eric WinzerDirector
- Scott PittmanDirector
- Offering amount
- $791.4K
- Amount sold
- $791.4K
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$849.1KraisedSep 2024 · 10 investors · Other Health CareRule 506(b)
▶$849.1KraisedSep 2024 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Scott PittmanDirector
- Paul MintzDirector
- C Eric WinzerDirector
- David JordenExecutive Officer, Director
- Peter ClausenExecutive Officer
- Offering amount
- $849.1K
- Amount sold
- $849.1K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$650.9KraisedMay 2024 · 11 investors · Other Health CareRule 506(b)
▶$650.9KraisedMay 2024 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David JordenExecutive Officer, Director
- C Eric WinzerDirector
- Peter ClausenExecutive Officer
- Scott PittmanDirector
- Paul MintzDirector
- Offering amount
- $650.9K
- Amount sold
- $650.9K
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$962.5KraisedDec 2023 · 9 investors · Other Health CareRule 506(b)
▶$962.5KraisedDec 2023 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Paul MintzDirector
- David JordenExecutive Officer, Director
- C Eric WinzerDirector
- Peter ClausenExecutive Officer
- Scott PittmanDirector
- Offering amount
- $962.5K
- Amount sold
- $962.5K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedAug 2023 · 9 investors · Other Health CareRule 506(b)
▶$1MraisedAug 2023 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Peter ClausenExecutive Officer
- C Eric WinzerDirector
- David JordenExecutive Officer, Director
- Paul MintzDirector
- Scott PittmanDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$407.8KraisedMay 2022 · 6 investors · Other Health CareRule 506(b)
▶$407.8KraisedMay 2022 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Scott PittmanDirector
- Paul MintZDirector
- David JordenExecutive Officer, Director
- C Eric WinzerDirector
- Peter ClausenExecutive Officer
- Offering amount
- $407.8K
- Amount sold
- $407.8K
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedMay 2022 · 26 investors · Other Health CareRule 506(b)
▶$3.5MraisedMay 2022 · 26 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David JordenExecutive Officer, Director
- Scott PittmanDirector
- Paul MintzDirector
- C Eric WinzerDirector
- Peter ClausenExecutive Officer
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedJun 2018 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedJun 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- LAWRENCE S ATINSKYDirector
- PAUL D MINTZDirector
- PETER A CLAUSENExecutive Officer
- DAVID E JORDENExecutive Officer, Director
- SCOTT M PITTMANDirector
- ERIC C WINZERDirector
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $500K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Nuo Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Nuo Therapeutics do?
- Nuo Therapeutics is a commercial-stage medical device company developing biodynamic therapies for wound care. Its flagship product, Aurix, is a hematogel that uses a patient's own platelets and plasma to promote healing.
- Who are Nuo Therapeutics's investors?
- Nuo Therapeutics's investors include Mundi Ventures.
- How much funding has Nuo Therapeutics raised?
- Nuo Therapeutics has disclosed $37.2M raised across 10 of its 11 known rounds.
- Where is Nuo Therapeutics headquartered?
- Nuo Therapeutics is headquartered in Houston, US.